A genetic defect resulting in mild low-renin hypertension
Open Access
- 18 August 1998
- journal article
- case report
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 95 (17) , 10200-10205
- https://doi.org/10.1073/pnas.95.17.10200
Abstract
Severe low-renin hypertension has few known causes. Apparent mineralocorticoid excess (AME) is a genetic disorder that results in severe juvenile low-renin hypertension, hyporeninemia, hypoaldosteronemia, hypokalemic alkalosis, low birth weight, failure to thrive, poor growth, and in many cases nephrocalcinosis. In 1995, it was shown that mutations in the gene (HSD11B2) encoding the 11β-hydroxysteroid dehydrogenase type 2 enzyme (11β-HSD2) cause AME. Typical patients with AME have defective 11β-HSD2 activity, as evidenced by an abnormal ratio of cortisol to cortisone metabolites and by an exceedingly diminished ability to convert [11-3H]cortisol to cortisone. Recently, we have studied an unusual patient with mild low-renin hypertension and a homozygous mutation in the HSD11B2 gene. The patient came from an inbred Mennonite family, and though the mutation identified her as a patient with AME, she did not demonstrate the typical features of AME. Biochemical analysis in this patient revealed a moderately elevated cortisol to cortisone metabolite ratio. The conversion of cortisol to cortisone was 58% compared with 0–6% in typical patients with AME whereas the normal conversion is 90–95%. Molecular analysis of the HSD11B2 gene of this patient showed a homozygous C→T transition in the second nucleotide of codon 227, resulting in a substitution of proline with leucine (P227L). The parents and sibs were heterozygous for this mutation. In vitro expression studies showed an increase in the Km (300 nM) over normal (54 nM). Because ≈40% of patients with essential hypertension demonstrate low renin, we suggest that such patients should undergo genetic analysis of the HSD11B2 gene.Keywords
This publication has 55 references indexed in Scilit:
- A New Compound Heterozygous Mutation in the 11 -Hydroxysteroid Dehydrogenase Type 2 Gene in a Case of Apparent Mineralocorticoid ExcessJournal of Clinical Endocrinology & Metabolism, 1997
- Apparent mineralocorticoid excess in a Brazilian kindredJournal Of Hypertension, 1997
- Apparent mineralocorticoid excess due to 11β‐hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardationClinical Endocrinology, 1996
- Diagnosis and treatment of a child with the syndrome of apparent mineralocorticoid excess type 1Acta Paediatrica, 1996
- Mineralocorticoid hypertension and congenital deficiency of 11β‐hydroxysteroid dehydrogenase in a family with the syndrome of‘apparent’mineralocorticoid excessClinical Endocrinology, 1995
- Cloning and tissue distribution of the human 1 lβ-hydroxysteroid dehydrogenase type 2 enzymeMolecular and Cellular Endocrinology, 1994
- 11β-Hydroxysteroid dehydrogenase in renal collecting duct cellsSteroids, 1994
- Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension researchThe Journal of Steroid Biochemistry and Molecular Biology, 1993
- Spironolactone-reversible rickets associated with 11β-hydroxysteroid dehydrogenase deficiency syndromeThe Journal of Pediatrics, 1986
- CLINICAL RESPONSE TO METYRAPONE AS INDICATED BY MEASUREMENT OF MINERALOCORTICOIDS AND GLUCOCORTICOIDS IN NORMAL CHILDRENClinical Endocrinology, 1981